A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Clinical trial NCT04119453 · TERMINATED
Trial details
- NCT number
- NCT04119453
- Sponsor
- Elevar Therapeutics
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-22
- Primary completion
- 2023-06-28
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.